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Edited by Lukas HuberAbstract Eﬀorts have been made to develop a chemoprevention
that selectively triggers apoptosis in malignant cancer cells.
Here, we demonstrated that a mutated Ha-Ras activity is re-
quired in Anisomycin-induced apoptosis in transformed keratino-
cytes. Anisomycin stimulates JNK activity and apoptosis in
oncogenic Ha-Ras positive cells, but not in normal keratinocytes.
This eﬀect was demonstrated in stably transfected cells with
dominant negative Ha-Ras, that protected transformed cells,
and oncogenic Ha-Ras that sensitized non-transformed cells to
Anisomycin-induced apoptosis. Lastly, the treatment of cells
with inhibitors of the JNK displayed resistance to Anisomycin in-
duced apoptosis. These data suggests that the oncogenic Ha-Ras
is important for Anisomycin-induced JNK activation and apop-
tosis in transformed keratinocytes.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ras genes have been shown to be a major participant in the
development and progression of a series of human tumors [1].
It has been shown recently that oncogenic Ras has a key role in
tumor maintenance and resistance to apoptosis [2]. The inﬂu-
ence of ras oncogene or wild type Ras expression on sensitiza-
tion to agent inducing apoptosis has been poorly studied and
has led to conﬂicting results. Ras expression was shown to
cause increased sensitivity to apoptosis induction by TNF-a
[3], and over expression of normal ras genes act as pro-
apoptotic proteins [4]. On the other hand, ras expression
inhibits drug- and UV-induced apoptosis [5], and is function-
ally involved in FGF-dependent suppression of apoptosis [6].
The mitogen-activated protein kinase (MAPK) family of pro-
teins belongs to distinct and evolutionarily conserved signal
transduction pathways that are activated by extracellular stim-
uli. In particular, c-Jun N-terminal kinase (JNK) and p38
pathways are activated by stress agents and correlate with
induction of apoptosis by these agents [7–9]. Anisomycin
(Ani) has been shown to activate eﬃciently a cellular stress re-
sponse involving the activation of JNKs [10]. Furthermore, it
was demonstrated that this stress response originates fromAbbreviations: Ani, Anisomycin; JNK, cJun N-terminal kinase;
Ha-Ras, Harvey-Ras
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lationally active ribosome are involved [11]. Using normal and
transformed mouse keratinocytes as model system, we have
investigated the role of oncogenic Ha-Ras on Ani-induced
apoptosis. Our observations demonstrate that Ani induces
apoptosis preferentially in oncogenic Ha-Ras transformed
cells, while cells expressing normal Ha-Ras were unaﬀected.
2. Materials and methods
2.1. Cells lines culture, and treatment conditions
The origin of the cell lines used in this study has been described else-
where [12]. Cells were cultured in Hams F-12 medium supplemented
with aminoacids and vitamins (Gibco Ltd., Paisley, Scotland), 10% fe-
tal bovine serum (FBS) and 80 lg/ml gentamicine. Cultures were main-
tained on plastic at 37 C in 5% CO2 humidiﬁed atmosphere.
For Ani treatments (Calbiochem, San Diego, CA) cells were plated
on six wells plates at a density of 3.5 · 10 cells, and DMSO dissolved
Ani was added at indicated concentration and times, the control cells
were treated with the similar volume of vehicle DMSO. Curcumin
(Sigma, St. Louis, MO) and SP600125 a JNK inhibitor (Calbiochem)
were added 1 h before Ani treatment.
2.2. Internucleosomal DNA fragmentation assay and DNA cell cycle
analysis
DNA was extracted from cells as described previously by Song et al.
[13]. Fragmented DNA samples were separated by electrophoresis on
1.5 agarose gel and visualized with ethidium bromide.
2.3. DNA cell cycle analysis
Cells were plated at 5 · 105/plate in 60 mm dishes and treated for
indicated times and harvested with Trypsin/EDTA, and ﬁxed in 70%
ethanol. Cells were washed two times with ice-cold PBS, and resus-
pended in 25 lg propidium iodide/ml and 50 lg RNase A/ml in PBS.
Samples were incubated at 37 C for 1 h. and DNA proﬁles were ana-
lyzed by FACS using a FACScan cytometer (Becton Dickinson).
2.4. Transfected cells
MCA3D transfected with active form of Ha-Ras (Q61L) or the
empty vector, and PDV cells transfected with dominant negative Ha-
Ras gene (Ras N17) or empty vector were previously described [14].
2.5. Activation of JNK and Ras expression
A cell monolayers were lysed in 300 ll of lysis buﬀer (100 mM so-
dium phosphate, pH 7.2, 1% NP-40, 150 mM NaCl, 5 mM EDTA,
10 mM b-glycerophosphate, 1 mM Na3VO4, 5 mM NaF, 10 lg/ml leu-
peptin, 1 lg/ml pepstatin, and 1 mM PMSF). Samples were separated
on a reducing 10% SDS–PAGE, and blotted onto PDV membrane
(Immobilon P, millipore, Bedford, MA). Activation of JNK was as-
sayed by immune-detection with antibody (Santa Cruz, CA) that rec-
ognized the activated (phosphorylated) form of JNK. Duplicated
ﬁlters were probed with antibody (Santa Cruz) that recognized both
phosphorylated and unphosphorylated forms of JNK to verify equal
loading. To determinate de expression level of Ha-Ras in PDV cells
transfected with Dominant negative Ha-Ras, parental and transfected
cells were seeded in 60 mm diameter plates (2 · 106 cells) and subject asblished by Elsevier B.V. All rights reserved.
Fig. 1. Anisomicin-induced internucleosomal DNA fragmentation in a Ha-Ras mutated PDV cells but not in normal Ha-Ras MCA3D cells. MCA-
3D and PDV cells (5 · 105) were seeded in six plate wells and treated with Anisomicin at 37 C. (A) Cells were treated with increased amounts of
Anisomicin for 16 h and assayed for internucleosomal DNA fragmentation. (B) Cells were treated with Anisomicin (0.5 lg/ml) for 8 h and subject to
DNA cell cycle analysis and % of apoptosis was observed as population cells containing a hypodiploid DNA contents in area into doted box included
in ﬁgures. (C) MCA3D cells were subject to long time of treatment with Anisomicin (1 lg/ml) and assayed as (A). Figures represent at least three
independent experiments.
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anti-Ha-Ras antibody (Santa Cruz), and reblotted against b-tubulin
(Sigma) to normalized Ha-Ras expression.Fig. 2. Anisomicin stimuli increases JNK-mediated phosphorylation
in PDV cells but not in MCA3D cells. (A) MCA3D and PDV cells
were seeded at 2.5 · 105 cells/well in six wells plates. Cells were treated
with 0.5 lg/ml Anisomicin from 15 to 90 min, and phospho-JNK and
total JNK were determined by Western blot analysis. (B) Cells were
pretreated with curcumin (Cur, 10 lM) or JNK inhibitor SP 600125
(SP, 10 lM) for 1 h, after this 0.5 lg/ml of Anisomicin was added for
additional 16 h, and analyzed by internucleosomal DNA fragmenta-
tion. (C) Cells were treated with inhibitors as above, except Anisomicin
treatment was for 8 h and subject to DNA Cell cycle analysis and
expressed as Table 1. (D) Cells were pretreated 1 h with Cur for 1 h,
and 0.5 lg/ml of Anisomicin was added for additional 1 h. JNK
phosphorylation was determined by Western blot. Results are repre-
senting three independent experiments.3. Results
3.1. Ani treatment induces apoptosis in Ha-Ras transformed cell
lines but not in immortalized MCA3D cell line
We selected for this study two epidermal cell lines: MCA3D
a normal immortalized keratinocytes with normal Ha-Ras;
and PDV cells a transformed keratinocytes with two normal
allele of normal Ha-Ras and one allele of oncogenic Ha-
Ras, for review see [15]. We compared the relative ability of
Ani to induce apoptosis in both cells lines. The results show
(Fig. 1A) that Ani treatment caused an internucleosomal
chromatin cleavage in PDV cells in a dose dependent form,
but this eﬀect was not observed in MCA3D. Quantiﬁcation
of apoptosis by propidium iodide staining and FACs analysis
(Fig. 1B) showed that 8 h of treatment with Ani induces DNA
fragmentation observed by population cells containing a
hypodiploid DNA contents. In contrast, no increase in
DNA fragmentation was observed in MCA3D cells. To deter-
mine the MCA3D resistance to Ani induced apoptosis, we
treated the cells at diﬀerent long periods of time with 1 lg/
ml (Fig. 1C). MCA3D displayed a resistance to apoptosis in-
duced by Ani, and a slight DNA fragmentation was observed
over 48 h of treatment.
3.2. Role of JNK on Ani-induced apoptosis
Ani has been shown to strongly activate a cellular stress
response involving the activation of SAPK/JNK [10], and
we studied the possibility that this MAP kinase plays a role
in the apoptosis sensibility of cells. We compared the relative
ability of Ani to activate JNK (Fig. 2A) in MCA3D and
PDV cells. When 0.5 lg/ml of Ani was added to PDV cell
culture, JNK activation was observed at 15 min of treatment
and maintained in the following periods of time, as deter-
mined by extent phosphorylation of this MAP kinase. When
MCA3D was treated in the same way as PDV then no acti-
vation of JNK was observed upon treatment with Ani,
although unphosphorylate form of JNK was present. To
asses whether JNK mediated Ani-induced apoptosis, we used
curcumin and SP600125, both inhibitors of JNK pathway
[16,17]. The results (Fig. 2B and C) demonstrated that curcu-
min and SP600125 protects against Ani-induced apoptosis in
Ha-Ras oncogenic positive cells. Pretreatment of the cells
with curcumin or SP600125 suppressed strongly the DNA
fragmentation and population cells containing a hypodiploid
DNA induced by Ani. We therefore, tested whether curcu-
min inhibits Ani-mediated phosphorylation of JNK by Wes-
tern blot analyses. As shown in Fig. 3D, pretreatment with
curcumin inhibited Ani-induced JNK-activation in PDV
and cells.
3.3. A dominant negative Ras mutant gene protected PDV cells
from Ani-induced apoptosis
Oncogenic Ha-Ras has been shown to be related to cellular
malignance, and to play an important role in tumoral progres-
sion [1]. We therefore investigated the possibility that Ha-Ras
activation could explain the sensibility of tumorigenic cells to
Ani induced-apoptosis. We treated with Ani the PDV cellclone transfected with a vector containing a dominant negative
RasN17 mutant gene, named RN7, and observed that a
RasN17 transfection conferred resistance to apoptosis that
shown as non DNA fragmentation or hypoploid DNA con-
tents (Fig. 3A and B). Clone RN7 expressed a high level of
Ha-Ras (endogenous and dominant negative Ha-Ras transfec-
ted gene) compared with control cells transfected with empty
vector (Fig. 3C).
Fig. 3. A Ha-Ras inhibition block Anisomicin-induced apoptosis. Cells were seeded at 2.5 · 105 cells/well. (A) Control cells or a RN clone stably
transfected with dominant negative Ha-Ras mutant (N17) were treated with Anisomicin (0.5 lg/ml) for 16 h to internucleosomal DNA fragmentation
assay. (B) PDV RN clone was treated wit Anisomicin (0.5 lg/ml) for eight hours and DNA cell cycle analysis was performed. (C) Western blot for
Ha-Ras expression in control cells and RN clone. Results are representing three independent experiments.
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apoptosis and JNK activation in MCA 3D cells
When we transfectedMCA3Dwith an active form of Ha-Ras
(3D-R) a strong morphological changes were observed, trans-
fected cells lost the epithelial phenotype and acquired more
ﬁbroblastic characteristics. When treated 3D-R with Ani cells
displayed typically morphological changes a hallmarks of
apoptosis (Fig. 4A), showing a DNA laddering, and enhanced
the hypodiploid DNA contents compared with a MCA3D
transfected with a empty vector, interestingly MCA3D trans-
fected with active Ha-Ras showing more elevated basal level
of apoptosis than cells transfected with empty vector (Fig. 4
B and C). The treatment of 3D-R with Ani by 30 min induced
a signiﬁcant activation of JNK while displaying an important
basal activation levels than 3D cells transfected with empty vec-
tor that did not responding to drug treatment (Fig. 4D).4. Discussion
Apoptosis is mainly the most potent defense against cancer
development, and eﬀorts have been made to develop a chemo-
prevention and therapeutics strategies that selectively trigger
apoptosis in malignant cancer cells. Mutated ras genes are
found in about 30% of all human cancers [1], and allow the pos-
sibility to diﬀerentially sensitized tumoral cells to drug-induced
apoptosis.
Paradoxically, Ha-Ras can either inhibit or promote apopto-
sis, with the outcome probably dependent upon the cell type
and the presence of other pro-apoptotic or anti-apoptotic sig-
nals [18]. While the mechanisms by which Ha-Ras provides
protection against apoptosis are being elucidated, and
although several reporters had shown that Ha-Ras sensizate
cells to apoptotic stimulus [3,19–22], less is understood about
how Ha-Ras can sensitize cells to diﬀerent apoptotic stimuli.
Our results indicate that oncogenic Ha-Ras transformed
PDV keratinocytes cells are highly sensitive to Ani-inducedapoptosis. These transformed cells produce squamous carci-
noma tumors upon injection in skin of nude mice, and acquire
more malignant phenotype in Ha-Ras dependent fashion to
TGF-b1 treatment [14,23]. In contrast, Ani-treatment had no
eﬀect in immortalized and non-tumorigenic MCA3D keratino-
cytes that have a normal Ha-Ras [15]. Sustained Ha-Ras activ-
ity is necessary for induction of apoptosis by Ani, as
demonstrated by the protection against apoptosis performed
by inhibition of Ha-Ras activity by dominant negative
N17-Ras (Fig. 3A and B). Furthermore, Ha-Ras activity is
also suﬃcient for induction of apoptosis by Ani, as shown
by the sensitivity conferred by transfection of activated
Ha-Ras (Q61L) into non-transformed cells (Fig. 4A–C).
JNK is a critical signaling component in the regulation
apoptosis [24], and activation of JNK by Ani that bind to or
alter the structure of 28S ribosomal RNA was proposed as
ribotoxic stress response in eukaryotic cells [11], and this ribo-
toxic stress could sensitize tumors cells to chemotherapy [25].
We found that Ani activated JNK in oncogenic Ha-Ras trans-
formed PDV cells, and normal immortalized MCA3D kerati-
nocytes cells were very little stimulated (Fig. 2A). The JNK
activation was necessary for the induction of apoptosis by
Ani in PDV cells, observed by using both JNK inhibitors cur-
cumin and SP600125 (Fig. 3B and C). The mechanism by
which Ha-Ras could sensitize cells to Ani-induced JNK activa-
tion remains not elucidate, as does the reason for which acti-
vated JNK is involved in triggering apoptotic mechanism.
Recent studies showed that JNK translocates to mitochon-
dria after genotoxic stress and inhibits the anti-apoptotic func-
tion of proteins belonging to Bcl2 family members [26], thereby
allowing the release of mitochondrial apoptogenic proteins to
cytosol as well cyto-c and Smac/Diablo [27], and subsequent
activation of caspases to promote apoptosis [28].
In resume, our data supports the conclusion that activation
of JNK is a major component of the mechanism of sensitiza-
tion by oncogenic Ha-Ras of keratinocytes transformed cells
to Ani-induced apoptosis. However, further analysis is neces-
Fig. 4. Oncogenic Ha-Ras confer sensibility to Anisomicin-induced apoptosis to resistant normal MCA3D cells. MCA3D cells stably transfected
with empty vector (3D-EV) or Q61L Ha-Ras mutant (3D-R) were seeded at 2.5 · 105 cells/well. (A) Morphological changes of cells after 16 h of
Anisomicin (0.5 lg/ml) treatment (magniﬁcation 40·). (B) Internucleosomal DNA fragmentation assay after 16 h with 0.5 lg/ml of Anisomicin.
(C) DNA cell cycle analysis after six hours of 0.5 lg/ml of Anisomicin treatment. (D) Western blot for JNK phosphorylation after 1 h of Anisomicin
treatment (0.5 lg/ml). Figures are representing at least two independent experiments.
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tizes cells to translation inhibition are important, and their
identiﬁcation will be critical for designing strategies for the
treatment of tumoral disease.
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